Bristol-Myers business development head Biondi departs

NEW YORK (Reuters) – Bristol-Myers Squibb Co’s (N:) head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp (NASDAQ:), the company said on Thursday.

A Bristol-Myers spokeswoman said Biondi decided to leave to pursue an external opportunity and that the U.S. drugmaker is actively searching for his successor. Biondi could not immediately be reached for comment.

Biondi joined Bristol-Myers in 2002 and had been in charge of business development, helping the company pursue strategic partnerships and deals, since 2015.

Bristol-Myers announced the Celgene acquisition last January and the deal closed on Nov. 28. In June, the company had said Biondi would be part of the combined company’s leadership.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.